Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
Reneuron stem cell retinitis pigmentosa.
Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of vision due to cells in the retina becoming damaged and eventually dying.
2a clinical trial of its hrpc cell therapy candidate in retinitis pigmentosa.
Reneuron group plc aim.
Cell based therapeutics developer reneuron group updated the market.
Pre clinical studies carried out in disease models by the our academic collaborators have demonstrated that when transplanted into the retina our hrpc technology has the potential to preserve existing photoreceptors.
Our hrpc stem cell therapy candidate for rp benefits from orphan drug designation in both europe and the us.
We have worked with world leading collaborators and academic institutions in the retinal disease field to successfully take our retinitis pigmentosa programme through pre clinical development.
Our exosomes are derived from our ctx human neural stem cell line.
Thu 10 september 2020 16 00 a a a.
From our ctx human neural stem cell line.
Clinical development of hrpc for retinitis pigmentosa a blindness causing disease of the retina is progressing in the us and we have the.
About reneuron we are a leading clinical stage stem cell business.